Clinical stage pharmaceutical company Moleculin Biotech Inc (Nasdaq:MBRX) announced on Thursday that Annamycin, its next-generation anthracycline, has received orphan drug designation from the European Medicines Agency (EMA) for the treatment of Acute Myeloid Leukaemia (AML).
Annamycin's non-cardiotoxic profile, validated in multiple US and European studies, underscores its potential in AML therapy. Clinical data from a European trial demonstrated a notable 60% preliminary complete response rate in second-line AML subjects, with overall interim rates reaching 39%. The drug's durability in responses is developing, with one subject achieving a durable complete response beyond one year.
The EMA's orphan drug designation for Annamycin acknowledges its potential to address rare, life-threatening conditions like AML. Benefits include reduced regulatory fees, clinical support, research grants and up to 10 years of market exclusivity in the European Union upon approval.
Annamycin currently has fast track status and orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory AML, in addition to orphan drug designation for the treatment of STS lung mets.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA